We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-10.83%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.11B
AUM Growth
-$229M
Cap. Flow
+$212M
Cap. Flow %
10.07%
Top 10 Hldgs %
55.22%
Holding
39
New
13
Increased
14
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$111M
2
GSK icon
GSK
GSK
+$78.8M
3
PRGO icon
Perrigo
PRGO
+$76.2M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$70.9M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.1M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$101M
2
EVHC
Envision Healthcare Holdings Inc
EVHC
+$62M
3
TSRO
TESARO, Inc.
TSRO
+$33.6M
4
KTWO
K2M Group Holdings, Inc
KTWO
+$27.4M
5
BIIB icon
Biogen
BIIB
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 83.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$208M 9.86%
2,800,000
-700,000
-20% -$33.6M
VTRS icon
2
Viatris
VTRS
$20.8B
$137M 6.5%
5,000,000
+1,250,000
+33% +$40.5M
AGN
3
CALL
DELISTED
Allergan plc
AGN
$134M 6.34%
+1,000,000
New +$164M
AGN
4
DELISTED
Allergan plc
AGN
$134M 6.34%
1,000,000
+100,000
+11% +$16.4M
UHS icon
5
Universal Health Services
UHS
$10.2B
$105M 4.98%
900,000
– –
MCK icon
6
McKesson
MCK
$104B
$96.7M 4.59%
875,000
+125,000
+17% +$15.6M
CELG
7
DELISTED
Celgene Corp
CELG
$96.1M 4.56%
+1,500,000
New +$111M
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$92.4M 4.38%
2,250,000
+175,000
+8% +$6.56M
PRGO icon
9
Perrigo
PRGO
$1.44B
$85.3M 4.04%
2,200,000
+1,200,000
+120% +$76.2M
GSK icon
10
GSK
GSK
$107B
$76.4M 3.63%
+1,600,000
New +$78.8M
BIIB icon
11
Biogen
BIIB
$30.9B
$75.2M 3.57%
250,000
-50,000
-17% -$16M
ATRA icon
12
Atara Biotherapeutics
ATRA
$72.6M
$66M 3.13%
76,000
+11,200
+17% +$10.4M
NKTR icon
13
Nektar Therapeutics
NKTR
$2.39B
$65.7M 3.12%
133,333
+33,333
+33% +$20.1M
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
$58.4M 2.77%
+600,000
New +$70.9M
THC icon
15
Tenet Healthcare
THC
$22.2B
$55.7M 2.64%
3,250,000
+1,700,000
+110% +$41.1M
BMY icon
16
CALL
Bristol-Myers Squibb
BMY
$129B
$52M 2.47%
+1,000,000
New +$53.7M
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$50.3M 2.39%
2,800,000
+1,050,000
+60% +$21.5M
BKD icon
18
Brookdale Senior Living
BKD
$3.55B
$50.3M 2.38%
7,500,000
+1,000,000
+15% +$8.39M
CAH icon
19
CALL
Cardinal Health
CAH
$53.7B
$44.6M 2.12%
+1,000,000
New +$52.1M
MNTA
20
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$44.2M 2.1%
4,000,000
+1,121,110
+39% +$15.6M
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$38.3B
$43.7M 2.08%
+600,000
New +$46.1M
AMAG
22
DELISTED
AMAG Pharmaceuticals
AMAG
$40.3M 1.91%
2,650,000
– –
MDCO
23
DELISTED
Medicines Co
MDCO
$38.3M 1.82%
2,000,000
– –
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.64B
$38.2M 1.81%
+350,000
New +$43.8M
THOR
25
DELISTED
Synthorx, Inc. Common Stock
THOR
$32.4M 1.54%
+1,862,116
New +$27M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Camber Capital Management held 39 positions worth $2.11B, down 9.8% from $2.34B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Camber Capital Management deployed $212M of net new capital in Q4 2018, opening 13 new positions and adding to 14 existing holdings. Its largest new stake was Celgene Corp: 1,500,000 shares worth $96.1M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 70% a quarter earlier.

On the sell side, the largest reduction was HCA Healthcare, an estimated $101M trimmed.

  • Camber Capital Management's largest Q4 2018 buy was Celgene Corp: 1,500,000 shares worth $96.1M.
  • Camber Capital Management added most to Perrigo in Q4 2018, an estimated $76.2M increase.
  • Camber Capital Management's biggest Q4 2018 reduction was HCA Healthcare, cutting an estimated $101M.
  • Camber Capital Management fully exited Envision Healthcare Holdings Inc in Q4 2018, selling an estimated $62M.
  • Camber Capital Management's ten largest holdings make up 55% of its $2.11B portfolio in Q4 2018.
  • Camber Capital Management opened 13 new positions and closed 3 in Q4 2018.
  • Camber Capital Management's portfolio value fell 9.8% quarter-over-quarter to $2.11B.

Based on Camber Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.